Clinical Trials Logo

Colon Cancer clinical trials

View clinical trials related to Colon Cancer.

Filter by:
  • Suspended  
  • Page 1

NCT ID: NCT05040568 Suspended - Colon Cancer Clinical Trials

A PHASE IB STUDY OF IMMUNOTHERAPY WITH EX VIVO PRE-ACTIVATED AND EXPANDED CB-NK CELLS IN COMBINATION WITH CETUXIMAB, IN COLORECTAL CANCER PATIENTS WITH MINIMAL RESIDUAL DISEASE (MRD)

Start date: February 28, 2022
Phase: Phase 1
Study type: Interventional

A study of immunotherapy with expanded CB-NK cells in combination with cetuximab, to evaluate activity against minimal residual disease in patients with colon cancer that have completed adjuvant treatment but are positive for ctDNA

NCT ID: NCT04108481 Suspended - Rectal Cancer Clinical Trials

Immunotherapy With Y90-RadioEmbolization for Metastatic Colorectal Cancer

iRE-C
Start date: October 5, 2020
Phase: Phase 1/Phase 2
Study type: Interventional

This clinical trial will be conducted as a single-center, open-label, Phase I/2 trial to evaluate the feasibility and safety of Yttrium-90 radioembolization (Y90-RE) in combination with a fixed dose of of immunotherapy (durvalumab - 750 mg) in subjects with liver-predominant, metastatic colorectal cancer (mCRC), which is mismatch repair proficient/microsatellite stable (pMMR/MSS).

NCT ID: NCT00909558 Suspended - Breast Cancer Clinical Trials

Safety and Effectiveness Study of Autologous Natural Killer and Natural Killer T Cells on Cancer

Start date: May 2009
Phase: Phase 1
Study type: Interventional

The purpose of this study is to assess the safety and effectiveness of natural killer (NK) cell and natural killer T (NKT) cell-based autologous adoptive immunotherapy in subjects with metastatic, treatment-refractory breast cancer, glioma, hepatocellular carcinoma, squamous cell lung cancer, pancreatic cancer, colon cancer or prostate cancer.

NCT ID: NCT00443573 Suspended - Colon Cancer Clinical Trials

Safety Study of Recombinant NAPc2 to Prevent Tumor Progression and Metastases in Metastatic Colon Cancer

Start date: December 2006
Phase: Phase 1/Phase 2
Study type: Interventional

This is a multicenter, two-stage trial with the goal of evaluating up to 100 subjects. This trial will be performed to initiate identification of a safe and effective dose of twice-weekly, subcutaneous rNAPc2 for the second-line treatment of metastatic colorectal carcinoma in combination with contemporary 5-FU-based chemotherapy.